Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management

摘要

Ibrutinib is a Bruton tyrosine kinase inhibitor approved in the US for the management of chronic lymphocytic leukaemia (CLL), previously treated mantle cell lymphoma (MCL) and Waldenstrom macroglobulinemia. Cutaneous manifestations have been reported in 2-27% of patients receiving ibrutinib, described as rash, petechiae and bruising (Byrd et al, 2013, 2014; Wang et al, 2013; O'Brien et al, 2014; Treon et al, 2015). These have variably resulted in dose reductions, treatment delays or drug discontinuation. Currently published descriptions of ibrutinib-associated rash are limited to case reports (Mannis et al, 2015). Little published experience is available on its evaluation and management, and guidelines regarding optimal clinical management have not been established. We sought to better define the clinicopathological features, management and outcomes of patients with ibrutinib-associated rash at our centre.